Diagnosing and treating patients with cancer as early as possible can reduce the risk of recurrence and improve chances for a cure. Evidence also suggests that early action against cancer – including in the form of early-stage treatments – can have benefits for healthcare systems. While the clinical potential of medicines in early-stage cancers is increasingly acknowledged, challenges remain to patients’ access to these medicines across Europe. Based on a systematic analysis of these challenges, the session will discuss actionable solutions to address them from a policy and healthcare system perspective. A special focus will be placed on the economic value of early diagnosis, treatment, and well-functioning cancer patient pathways.

Sponsored by MSD